Roivant joins RNA splicing push with Eisai deal
pharmaphorum
JANUARY 6, 2022
The compound, called H3B-8800, is currently in phase 1 testing in the US and Europe in patients with myelodysplastic syndrome (MDS) who carry mutations in splicing factor 3B subunit 1 (SF3B1) by Eisai’s H3 Biomedicine subsidiary.
Let's personalize your content